Please login to the form below

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Dupixent bounce-back helps stem diabetes declines at Sanofi

Another Regeneron-partnered drug – and another key component for Sanofi’s specialty medicines drive – is cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab), and while sales rose 55% year-on-year to 62m ... At the moment, Sanofi is losing

Latest news

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

This puts it ahead of its fellow PCSK9 product and rival, however Sanofi and Regeneron unveiled strong strong cardiovascular outcomes data from their ODYSSEY trial in combination with the huge cut ... However, the majority of patients in Europe who could
Esperion craters as deaths mar atherosclerosis drug study

Esperion is hoping to position bempedoic as a once-daily, oral alternative to PCSK9 inhibitor such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), which are given by ... Esperion recently reported phase II data showing
Praluent can stay on market for now, says US court

Praluent was approved in the US first, but Amgen has so far won the key rounds in the legal dispute over PCSK9 inhibitor intellectual property rights. ... This decision is important for patients in the US who will continue to have access to Praluent
New outcomes data could unlock Repatha's potential, says Amgen

PCSK9 inhibitor Repatha (evolocumab) was approved on the strength of data showing it could reduce low-density lipoprotein cholesterol (LDL-c), but health insurers and pharmacy benefit managers in the US ... for their rival PCSK9 inhibitor Praluent
Amgen wins block on sales of Sanofi/Regeneron's Praluent

Amgen has won another round in its lawsuit with Sanofi and Regeneron over patent rights to the new PCSK9 inhibitor class of cholesterol-lowering drugs. ... The decision follows an earlier victory for Amgen as it defended patents on its rival PCSK9

More from news
Approximately 10 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Pharma deals during November 2014

AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Director – Head of Public Affairs: Neg

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Editorial Director – Medical Education: Neg

Account Director - Digital: Great salary and benefits

Scientific Team Lead: Competitive Salary

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Director: Highly Competitive Salary &Benefits

Project / Account Manager (Medical Education): Salary TBC

Account Manager, Healthcare Advertising: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Experienced Editor, London, Medical Communications: Competitive package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director – Global Healthcare PR: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Executive – Medical Communications: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Account Director: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Associate Medical Director: Highly Competitive

Director Healthcare PR Communications: Salary TBC

Associate Medical Director: Salary TBC

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...